SLC5A2 and Iron deficiency anemia: Further evidence regarding any interaction between SGLT2 inhibitors and intravenous iron should soon be provided by the HEART‐FID (Ferric Carboxymaltose in Heart Failure With Iron Deficiency) trial (ClinicalTrials.gov identifier NCT03037931).12